NEW MEDICINES, NOVEL INSIGHTS
Accelerating development of cell and gene therapies
Download the executive summary
Chris Learn, Ph.D., P.M.P.
Senior Vice President, Head of the Cell and Gene Center of Excellence
NEW MEDICINES, NOVEL INSIGHTS
Download the executive summary
Chris Learn, Ph.D., P.M.P.
Senior Vice President, Head of the Cell and Gene Center of Excellence
Cell and gene therapies (CAGTs) offer extraordinary hope to patients with advanced cancers and genetic diseases but pose unprecedented challenges for sponsors. In this report, Parexel experts share insights that can bring these complex treatments to market faster and more efficiently.
IN THIS REPORT
SECTION 1
To gain a deeper understanding of journeys before, during, and after CAR-T therapy for hematological malignancy, we gathered insights and feedback from patients, caregivers and healthcare professionals (HCPs).
Go to section
SECTION 2
With a growing global CAGT pipeline, sponsors should develop data-informed development paths to support their product applications. Prepared therapy developers set themselves up for the best chance of success for expedited regulatory review, to bring products to patients — quicker. In this section, Parexel experts and former regulators share their insights.
Go to section
SECTION 3
Current research processes and infrastructure can’t fully support the requirements of cell and gene therapy protocol development and delivery. Now is the time for new approaches, to futureproof clinical development as the product pipeline continues to grow. This section sets out the perspectives and insight to build partnerships throughout the cell and gene therapy ecosystem, to accelerate innovation and therapy delivery.
Go to section
SECTION 4
Cell and gene therapies do not fit existing frameworks for valuing, pricing, and reimbursing pharmaceuticals, but there is an opportunity to change the narrative. With a focus on communicating value, and aligning regulatory, clinical and market access strategies earlier and simultaneously, hear from Parexel’s experts on the trends that could impact patient access and market success.
Go to section